Cancer Institute A national cancer institute
designated cancer center
Profile http://med.stanford.edu/profiles/cancer/researcher/Peter_Greenberg/
Email this profile
Portrait View Larger

Peter Greenberg

Academic Appointments

  • Professor of Medicine (Hematology), Emeritus

Key Documents

Contact Information

  • Clinical Offices
    Hematology Clinic 875 Blake Wilbur Dr Clinic C MC 5820 Stanford, CA 94305
    Tel Work (650) 498-6000 Fax (650) 498-5030
  • Academic Offices
    Personal Information
    Email Tel (650) 725-8355
    Not for medical emergencies or patient use

Professional Overview

Clinical Focus

  • Cancer> Hematology
  • Hematology
  • Myelodysplastic Syndromes

Administrative Appointments

  • Coordinator, International Working Group for Prognosis in MDS (2009 - 2013)
  • Chair, National Comprehensive Cancer Network Myelodysplasitic Syndromes Practice Guidelines Panel (1997 - 2013)
  • Director, Stanford MDS Center (1998 - 2013)
  • Head, Hematology Section, VA Palo Alto Health Care System (1979 - 2005)
  • Acting Chief, Medical Service, VA Palo Alto Health Care System (1978 - 1979)

Honors and Awards

  • International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)

Boards, Advisory Committees, Professional Organizations

  • Member, American Society of Hematology (1972 - present)
  • Member, Eastern Cooperative Oncology Group, Leukemia Committee (1993 - present)

Professional Education

Medical Education: George Washington University DC (1963)
Fellowship: Stanford University School of Medicine CA (1971)
Residency: Barnes Hospital MO (1965)
Residency: Stanford University School of Medicine CA (1968)
Board Certification: Hematology, American Board of Internal Medicine (1976)
Board Certification: Internal Medicine, American Board of Internal Medicine (1970)
View All 9

Community and International Work

Scientific Focus

Current Research and Scholarly Interests

The major direction of research in my laboratory is to determine the role and mechanisms of hemopoietic dysregulation in human myeloid malignancies. The relation between molecular changes and cellular phenotype / pathophysiology is being explored using microarray and next generation technologies to evaluate differential gene expression profiles of MDS and AML marrow cells. The impact of cytokines and biologic response modifiers on these molecular features and hemopoietic response is being examined in clinical investigations with MDS and AML patients in therapeutic clinical trials with these agents.

Publications

Publication tag cloud

Publication Topics

View All 77

Stanford Medicine Resources:

Footer Links: